Effects on Cellulite Appearance

Body Fat Disorder Clinical Trial

— EFC  

Official title:

Feasibility Study of CoolSculpting Effects on Cellulite Appearance

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04876118
• Other study ID #: ZA20-002
• Status: Recruiting
• Phase: N/A
• Start date: November 13, 2020
• Est. completion date: November 2022

Study information

• Verified date: May 2021
• Source: Zeltiq Aesthetics
• Contact: Tonia N Madere
• Phone: 925-474-2537
• Email: tonia.madere[@]allergan.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Evaluate the safety and feasibility effecting the appearance of cellulite on the thigh using CoolSculpting.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 60
• Est. completion date: November 2022
• Est. primary completion date: November 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 22 Years to 65 Years

Eligibility

Inclusion Criteria

• Female subjects > 22 years of age and < 65 years of age.
• Subject has clearly visible cellulite on the intended treatment area (thighs), which in the Investigator's opinion, may benefit from the treatment.
• Subject has not had weight change exceeding 5% in the preceding month.
• Subject agrees to maintain her weight (i.e., within 5%) by not making any major changes in diet or exercise routine during the course of the study.
• Subject has read and signed a written informed consent form. Exclusion Criteria
• Subject has had a surgical procedure(s) in the area of intended treatment.
• Subject has had an invasive fat reduction procedure (e.g., liposuction, mesotherapy) in the area of intended treatment.
• Subject has had a non-invasive fat reduction, body contouring, cellulite reduction and/or skin tightening procedure in the area of intended treatment within the past 4 months.
• Presence of significant suntan in the thighs.
• Inability to avoid sun exposure in the thighs.
• Subject has a history of hernia in or adjacent to the areas to be treated.
• Subject needs to administer or has a known history of subcutaneous injections into the area of intended treatment (e.g., heparin, insulin) within the past month.
• Subject has a known history of cryoglobulinemia, cold urticaria, cold agglutinin disease, or paroxysmal cold hemoglobinuria.
• Subject has a known history of Raynaud's disease, or any known condition with a response to cold exposure that limits blood flow to the skin.
• Subject has a history of bleeding disorder or is taking any medication that in the Investigator's opinion may increase the subject's risk of bruising.
• Subject has known sensitivity or allergy to isopropyl alcohol and propylene glycol.
• Subject is taking or has taken diet pills or supplements within the past month.
• Subject has any dermatological conditions, such as moderate to excessive skin laxity, or scars in the location of the treatment sites, that may interfere with the treatment or evaluation (stretch marks is not an exclusion).
• Subject has an active implanted device such as a pacemaker, defibrillator, implants (e.g. buttock implants), or drug delivery system.
• Subject is pregnant or intending to become pregnant during the study period (in the next 9 months).
• Subject is lactating or has been lactating in the past 6 months.
• Subject is unable or unwilling to comply with the study requirements.
• Subject is currently enrolled in a clinical study of any other unapproved investigational drug or device.
• Any other condition or laboratory value that would, in the professional opinion of the Investigator, potentially affect the subject's response or the integrity of the data or would pose an unacceptable risk to the subject.

Related Conditions & MeSH terms

• Body Fat Disorder
• Cellulite

Intervention

Device:
• The ZELTIQ System
The CoolSculpting machine will be used to perform the treatments.

Locations

Country	Name	City	State
United States	Innovation Research Center	Pleasanton	California

Sponsors (1)

Lead Sponsor	Collaborator
Zeltiq Aesthetics

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	visible changes in the treated areas on Photos	Comparison of baseline and 12-week post-final treatment photographs to assess visible changes in the treated areas.	one-month post final data collection
Secondary	AE's	The frequency of device and procedure-related adverse events (AEs), including device-related serious adverse events (SADEs), will be summarized. Safety Endpoint:	one-month post final data collection